To read this content please select one of the options below:

SARS-CoV-2 seroprevalence study after the first wave among persons living and working in an overcrowded Swiss prison

Laurent Gétaz (Division of Prison Health, Geneva University Hospitals, University of Geneva, Geneva, Switzerland and Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Thônex, Switzerland)
Hans Wolff (Division of Prison Health, Geneva University Hospitals, Thônex, Switzerland)
Leonel Gonçalves (Division of Prison Health, Geneva University Hospitals, Thônex, Switzerland)
Giuseppe Togni (Microbiology Lab, Unilabs Coppet Core Lab Ouest, Coppet, Switzerland)
Silvia Stringhini (Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland and University Center for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland)
Komal Chacowry Pala (Division of Prison Health, Geneva University Hospitals, Thônex, Switzerland)
Anne Iten (Infection Control Program, Geneva University Hospitals, Geneva, Switzerland)
Idris Guessous (Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland and Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland)
Laurent Kaiser (Geneva Center for Emerging Viral. Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland and Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland)
Francois Chappuis (Division and Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland and Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland)
Stéphanie Baggio (Division of Prison Health, Geneva University Hospitals, Thônex, Switzerland and Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland)

International Journal of Prisoner Health

ISSN: 1744-9200

Article publication date: 24 October 2022

Issue publication date: 5 September 2023

42

Abstract

Purpose

Prisons can be epicentres of infectious diseases. However, empirical evidence on the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in prison is still scarce. This study aims to estimate the seroprevalence rates of anti-SARS-CoV-2 in the largest and most crowded Swiss prison and compare them with the seroprevalence rate in the general population.

Design/methodology/approach

A cross-sectional study was conducted in June 2020, one month after the first wave of SARS-CoV-2 in Switzerland. Groups included: people living in detention (PLDs) detained before the beginning of the pandemic (n = 116), PLDs incarcerated after the beginning of the pandemic (n = 61), prison staff and prison healthcare workers (n = 227) and a sample from the general population in the same time period (n = 3,404). The authors assessed anti-SARS-CoV-2 IgG antibodies.

Findings

PLDs who were incarcerated before the beginning of the pandemic had a significantly lower seroprevalence rate [0.9%, confidence interval (CI)95%: 0.1%–5.9%] compared to the general population (6.3%, CI 95%: 5.6–7.3%) (p = 0.041). The differences between PLDs who were incarcerated before and other groups were marginally significant (PLDs incarcerated after the beginning of the pandemic: 6.6%, CI 95%: 2.5%–16.6%, p = 0.063; prison staff CI 95%: 4.8%, 2.7%–8.6%, p = 0.093). The seroprevalence of prison staff was only slightly and non-significantly lower than that of the general population.

Originality/value

During the first wave, despite overcrowding and interaction with the community, the prison was not a hotspot of SARS-CoV-2 infection. Preventive measures probably helped avoiding clusters of infection. The authors suggest that preventive measures that impact social welfare could be relaxed when overall circulation in the community is low to prevent the negative impact of isolation.

Keywords

Acknowledgements

The authors would like to thank all the collaborators of the division of prison health of the Geneva University Hospitals (HUG), the staff of the Unit of Population Epidemiology of the HUG, the team of the Division of Laboratory Medicine Primary Care Division of the HUG and the staff of the Unilabs Laboratory in Coppet, in particular Jacqueline Bizet. A special thanks to Elvire Rubaviza for project coordination, to Daphne Doomun and Ianis Doomun for compiling the data and to Agathe Cornu-Debreilly, Mathieu Lutz, Christian-Jean Sordet, Vincent Tan and Tin Vo for data collection.

Citation

Gétaz, L., Wolff, H., Gonçalves, L., Togni, G., Stringhini, S., Chacowry Pala, K., Iten, A., Guessous, I., Kaiser, L., Chappuis, F. and Baggio, S. (2023), "SARS-CoV-2 seroprevalence study after the first wave among persons living and working in an overcrowded Swiss prison", International Journal of Prisoner Health, Vol. 19 No. 3, pp. 392-399. https://doi.org/10.1108/IJPH-01-2022-0002

Publisher

:

Emerald Publishing Limited

Copyright © 2022, Emerald Publishing Limited

Related articles